Table 3: Response to T-DM1.
| Response | Number of patients (%) |
| Complete response | 3 (5%) |
| Partial response | 19 (30%) |
| Long stable disease (≥ 6 months) | 9 (14%) |
| Stable disease (< 6 months) | 9 (14%) |
| Progressive disease | 21 (33%) |
| Not evaluable | 2 (3%) |
| Response rate | 35% |
| Clinical benefit rate | 49% |
| Median time to treatment failure, months (range) | 4.0 (0.7-26.0) |